{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '6.2.7', 'Recording of adverse events', 'Adverse events will be recorded on electronic case report forms (eCRFs) using a recognized', 'medical term or diagnosis that accurately reflects the event. Adverse events will be assessed', 'by the treating physician (i.e., Sub-Investigator, Principal Investigator) for severity,', 'relationship to the investigational product, and possible etiologies. Adverse event assessments', 'will then be verified by the Principal Investigator who will also determine whether the event', 'meets criteria of an SAE and therefore requires immediate notification to AstraZeneca.', 'The following variables will be collected for each AE:', 'AE (verbatim)', 'The date when the AE started and stopped', 'Changes in NCI CTCAE grade and the maximum CTCAE grade', 'attained', 'Whether the AE is serious or not', 'Causality rating against olaparib (yes or no)', 'Action taken with regard to olaparib', 'Causality rating against testosterone (yes or no)', 'Action taken with regard to testosterone', 'Outcome', 'In addition, the following variables will be collected for SAEs as applicable:', 'Date AE met criteria for serious AE', 'Date treating physician (i.e. Sub-Investigator, Principal Investigator)', 'became aware of serious AE', 'Reason AE is considered serious', 'Date of hospitalization', 'Date of discharge', 'Probable cause of death', 'Date of death', 'Autopsy performed', 'Description of AE', 'Causality assessment in relation to Study procedure(s)', 'Events, which are unequivocally due to disease progression, should not be reported as an AE', 'during the study.', 'Time period for collection of adverse events', 'Adverse events and serious adverse events will be recorded from time of first dose of study', 'drug(s), throughout the treatment period and including the follow-up period (30 days after the', 'last dose of olaparib or testosterone, whichever occurred most recently).', '49(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'During the course of the study all AEs and SAEs should be proactively followed up for each', 'subject. Every effort should be made to obtain a resolution for all events, even if the events', 'continue after discontinuation/study completion.', 'If a subject discontinues from treatment for reasons other than disease progression, and', 'therefore continues to have tumor assessments, drug or procedure-related SAEs must be', 'captured until the patient is considered to have confirmed PD and will have no further tumor', 'assessments.', 'The treating physician (i.e. Sub-Investigator, Principal Investigator) is responsible for', 'following all SAEs until resolution, until the subject returns to baseline status, or until the', 'condition has stabilized with the expectation that it will remain chronic, even if this extends', 'beyond study participation.', '6.2.7.1', 'Adverse events after the 30 day follow up period', 'For Pharmacovigilance purposes and characterization, any case of MDS/AML or new primary', 'malignancy occurring after the 30 day follow up period should be reported to AstraZeneca', 'Patient Safety whether it is considered a non-serious AE [e.g., non-melanoma skin cancer] or', \"SAE, and regardless of investigator's assessment of causality or knowledge of the treatment\", 'arm. Investigators will be asked during the regular follow up for overall survival if the patient', 'has developed MDS/AML or a new primary malignancy and prompted to report any such', 'cases.', 'At any time after a patient has completed the study, if an Investigator learns of any SAE', 'including sudden death of unknown cause, and he/she considers there is a reasonable', 'possibility that the event is causally related to the investigational product, the investigator', 'should notify AstraZeneca, Patient Safety.', 'If patients who are gaining clinical benefit are allowed to continue study treatment post data', 'cut off and/or post study completion then all SAEs must continue to be collected and reported', 'to Patient Safety within the usual timeframe.', 'Otherwise, after study treatment completion (i.e., after any scheduled post treatment follow-up', 'period has ended) there is no obligation to actively report information on new AEs or SAEs', 'occurring in former study patients. This includes new AEs/SAEs in patients still being', 'followed up for survival but who have completed the post treatment follow up period (30', 'days).', 'Follow-up of unresolved adverse events', \"Any AEs that are unresolved at the subject's last visit in the study are followed up by the\", 'treating physician (i.e. Sub-Investigator, Principal Investigator) for as long as medically', 'indicated, but without further recording in the eCRF. After 90 days, only subjects with', 'ongoing investigational product-related SAEs will continue to be followed for safety.', '50(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}